Northern Trust
OTLK icon

Northern Trust’s Outlook Therapeutics OTLK Stock Holding History

Northern Trust’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Buy
237,561
+170,171
+253% +$106K ﹤0.01% 3740
2026
Q1 		$13.9K Hold
67,390
– – ﹤0.01% 4358
2025
Q4 		$106K Buy
67,390
+41,321
+159% +$66K ﹤0.01% 4127
2025
Q3 		$27.6K Sell
26,069
-12,927
-33% -$22.4K ﹤0.01% 4348
2025
Q2 		$62.4K Sell
38,996
-87,959
-69% -$140K ﹤0.01% 4199
2025
Q1 		$155K Buy
126,955
+15,205
+14% +$26.7K ﹤0.01% 4009
2024
Q4 		$211K Sell
111,750
-7,119
-6% -$29.3K ﹤0.01% 3973
2024
Q3 		$635K Buy
118,869
+35,432
+42% +$259K ﹤0.01% 3513
2024
Q2 		$616K Buy
83,437
+22,324
+37% +$179K ﹤0.01% 3429
2024
Q1 		$730K Sell
61,113
-7,570
-11% -$61.2K ﹤0.01% 3428
2023
Q4 		$541K Buy
68,683
+5,866
+9% +$49.6K ﹤0.01% 3513
2023
Q3 		$278K Buy
62,817
+52
+0.1% +$1.15K ﹤0.01% 3697
2023
Q2 		$2.18M Buy
62,765
+2,646
+4% +$72.1K ﹤0.01% 2959
2023
Q1 		$1.31M Buy
60,119
+12,809
+27% +$287K ﹤0.01% 3120
2022
Q4 		$1.02M Sell
47,310
-1,507
-3% -$32.8K ﹤0.01% 3247
2022
Q3 		$1.19M Buy
48,817
+72
+0.1% +$1.67K ﹤0.01% 3254
2022
Q2 		$995K Sell
48,745
-329
-0.7% -$9.46K ﹤0.01% 3344
2022
Q1 		$1.75M Buy
49,074
+8,197
+20% +$256K ﹤0.01% 3162
2021
Q4 		$1.11M Sell
40,877
-889
-2% -$31.7K ﹤0.01% 3499
2021
Q3 		$1.81M Sell
41,766
-2,255
-5% -$109K ﹤0.01% 3341
2021
Q2 		$2.19M Buy
44,021
+35,346
+407% +$1.64M ﹤0.01% 3310
2021
Q1 		$390K Buy
8,675
+3,927
+83% +$150K ﹤0.01% 3897
2020
Q4 		$123K Sell
4,748
-335
-7% -$7K ﹤0.01% 4074
2020
Q3 		$73K Buy
5,083
+1,368
+37% +$30.5K ﹤0.01% 4035
2020
Q2 		$96K Buy
3,715
+2,151
+138% +$38.4K ﹤0.01% 3932
2020
Q1 		$19K Buy
+1,564
New +$25.9K ﹤0.01% 4095

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM

Northern Trust's OTLK Position: Q2 2026 in Review

Northern Trust increased its Outlook Therapeutics (OTLK) stake by 253% in Q2 2026, buying an estimated $106K and bringing the position to 237,561 shares worth $378K. The position accounts for ﹤0.01% of the portfolio, ranked #3740.

Northern Trust first reported a position in OTLK in Q1 2020 and has held it in 26 quarters since. The position peaked at $2.19M in Q2 2021. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Northern Trust held 237,561 shares of Outlook Therapeutics worth $378K as of Q2 2026.
  • Northern Trust bought 170,171 Outlook Therapeutics shares in Q2 2026, an estimated $106K.
  • Outlook Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3740 holding.
  • Northern Trust first reported a position in Outlook Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Northern Trust's Outlook Therapeutics position peaked at $2.19M in Q2 2021.
  • 69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.